Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NTM-1633 in healthy adults
NCT03603665Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTM-1633 in botulism (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Adverse Events, Changes in Laboratory Values and 3 more. Started Sep 2018; status: completed.
02
Drugs
NTM-1633
03
Conditions
botulism
Beyond the preview
Go deeper on NCT03603665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603665.